We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals, Inc.
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

Back to rankings

103 hedge funds and large institutions have $622M invested in Dicerna Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,200% more call options, than puts

Call options by funds: $133K | Put options by funds: $1K

163% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 19

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

8% more funds holding

Funds holding: 95 → 103 (+8)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

26% less capital invested

Capital invested by funds: $838M → $622M (-$216M)

Holders
103
Holders Change
+8
Holders Change %
+8.42%
% of All Funds
2.3%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
22
Increased
50
Reduced
19
Closed
13
Calls
$133K
Puts
$1K
Net Calls
+$132K
Net Calls Change
+$122K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$17.9M
2
State Street
State Street
Massachusetts
+$16.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.89M
4
RI
RTW Investments
New York
+$5.87M
5
SCM
Sio Capital Management
New York
+$5.83M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.4M
2
BM
Bridger Management
New York
-$9.95M
3
EC
EcoR1 Capital
California
-$6.39M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.66M
5
SSA
Schonfeld Strategic Advisors
New York
-$2.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$3.56M +$4.37M +332,615 New
Federated Hermes
27
Federated Hermes
Pennsylvania
$3.54M +$1.04M +79,058 +31%
Charles Schwab
28
Charles Schwab
California
$3.02M +$698K +53,037 +23%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.33M +$429K +32,652 +18%
EU
30
Emory University
Georgia
$1.84M +$2.27M +172,524 New
UONDDL
31
University of Notre Dame du Lac
Indiana
$1.82M +$2.25M +170,734 New
OFM
32
Omega Fund Management
Massachusetts
$1.79M -$740K -56,300 -25%
Citigroup
33
Citigroup
New York
$1.79M +$2.03M +154,352 +1,216%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$1.77M -$281K -21,400 -11%
Invesco
35
Invesco
Georgia
$1.51M +$1.86M +141,438 New
Millennium Management
36
Millennium Management
New York
$1.32M +$250K +19,009 +18%
DCM
37
DAFNA Capital Management
California
$1.27M – – –
Two Sigma Investments
38
Two Sigma Investments
New York
$1.24M +$453K +34,433 +42%
Allianz Asset Management
39
Allianz Asset Management
Germany
$1.19M +$1.14M +86,567 +352%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.16M +$239K +18,200 +20%
FI
41
Fosun International
China
$1.15M +$1.5M +113,938 New
TA
42
Teachers Advisors
New York
$1.14M +$192K +14,580 +16%
TCIM
43
TIAA CREF Investment Management
New York
$1.04M +$124K +9,429 +11%
Morgan Stanley
44
Morgan Stanley
New York
$995K +$197K +14,989 +19%
SSA
45
Schonfeld Strategic Advisors
New York
$918K -$2.53M -192,400 -69%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$900K +$194K +14,729 +21%
Swiss National Bank
47
Swiss National Bank
Switzerland
$807K +$132K +10,000 +15%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$718K +$348K +26,483 +65%
MC
49
Matisse Capital
Oregon
$620K – – –
AQR Capital Management
50
AQR Capital Management
Connecticut
$538K +$80.5K +6,120 +14%
1
2
3 4 5

DRNA Hedge Fund Activity: Q4 2018 in Review

103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2018, worth a combined $622M — down 26% from $838M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new DRNA positions and 13 closed out — a net gain of 9 holders — while 50 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $17.9M. The largest seller was RA Capital Management, cutting an estimated $19.4M.

  • 103 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2018, up from 95 in Q3 2018.
  • Funds reported $622M of Dicerna Pharmaceuticals, Inc. stock for Q4 2018, down 26% quarter-over-quarter.
  • 22 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2018 and 13 closed out, a net change of +9 holders.
  • The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2018 was BlackRock, an estimated $17.9M added.
  • The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2018 was RA Capital Management, an estimated $19.4M sold.

Based on aggregated 13F filings for Q4 2018.